Your browser doesn't support javascript.
Increased circulating levels of angiotensin-(1-7) in severely ill COVID-19 patients.
Valle Martins, Ana Luiza; da Silva, Filipe Alex; Bolais-Ramos, Lucas; de Oliveira, Gisele Capanema; Ribeiro, Renata Cunha; Pereira, Danilo Augusto Alves; Annoni, Filippo; Diniz, Mirella Monique Lana; Silva, Thuanny Granato Fonseca; Zivianni, Bruna; Cardoso, Alexandre Carvalho; Martins, Juliana Carvalho; Motta-Santos, Daisy; Campagnole-Santos, Maria José; Taccone, Fabio Silvio; Verano-Braga, Thiago; Santos, Robson Augusto Souza.
  • Valle Martins AL; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • da Silva FA; Hospital Mater Dei, Intensive Care Unit, Belo Horizonte, Brazil.
  • Bolais-Ramos L; These authors contributed equally.
  • de Oliveira GC; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Ribeiro RC; These authors contributed equally.
  • Pereira DAA; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Annoni F; These authors contributed equally.
  • Diniz MML; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Silva TGF; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Zivianni B; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Cardoso AC; Waters Corporation, São Paulo, Brazil.
  • Martins JC; Dept of Intensive Care, Hôpital Erasme, Université Libre de Bruxelles (ULB), Brussels, Belgium.
  • Motta-Santos D; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Campagnole-Santos MJ; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Taccone FS; Fundação Hospitalar do Estado de Minas Gerais - FHEMIG, Belo Horizonte, Brazil.
  • Verano-Braga T; National Institute of Science and Technology in Nano Biopharmaceutics (INCT-NanoBiofar) - Laboratory of Hypertension, Institute of Biological Sciences, Federal University of Minas Gerais, Belo Horizonte, Brazil.
  • Santos RAS; Fundação Hospitalar do Estado de Minas Gerais - FHEMIG, Belo Horizonte, Brazil.
ERJ Open Res ; 7(3)2021 Jul.
Article in English | MEDLINE | ID: covidwho-1339115
ABSTRACT
This letter reports an unexpected increase of the ACE2 product angiotensin-(1-7) and a parallel decrease of its substrate angiotensin II, suggesting a dysregulation of the renin-angiotensin system towards angiotensin-(1-7) formation in #COVID19 patients https//bit.ly/3xFXuTU.
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Year: 2021 Document Type: Article Affiliation country: 23120541.00114-2021

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Language: English Year: 2021 Document Type: Article Affiliation country: 23120541.00114-2021